Prevalence of immune reconstitution inflammatory syndrome
The overall prevalence of IRIS was 38% at the study visit. The prevalence of IRIS in male children was higher than in female children, that is, 48 vs. 31% (OR 2.02, 95% CI 1.06–3.86, P = 0.023). Unmasking IRIS events accounted for 77% of the episodes compared with 23% of the paradoxical IRIS events. The prevalence of IRIS was found to be highest in the 5–12-year-old age group with a median age of 6.75 years. The prevalence of IRIS was highest in the first month of ART, followed by the next 3 months period, and least in the 3–6 months of ART.
Clinical pattern of immune reconstitution inflammatory syndrome
The clinical presentation of patients with IRIS is shown in Table 2. TB was the most common IRIS presentation accounting for 25 (29%) of the patients with a prevalence of 15.4% (25/162). Of mycobacterial-IRIS, 20 (80%) had pulmonary TB, two had disseminated TB, and three had Bacille–Calmette–Guerin (BCG) lymphadenitis (BCG-IRIS). Fourteen patients (8.6% prevalence) had no prior TB diagnosis and were considered ART-associated TB (i.e. unmasking TB-IRIS). Paradoxical TB-IRIS occurred in 11 children who had a prior TB diagnosis with an overall prevalence of 6.8%.
The other presentations were worsening or recurrence of pruritic papular eruption and extensive oral candidiasis (seven, 7.5%), acute bacterial pneumonia (six, 6.5%), verruca planus (four, 6.5%), and taenia skin manifestations (four, 4.3%) with extensive involvement of the face, hair, and trunk and with patients having reported the flaring up of preexisting scanty lesions.
Clinical findings before antiretroviral therapy and at interview
The most common historical feature was previous opportunistic infection treatment in the past 1 year, which was present in 61.7% of patients (100/162), but this was not predictive of IRIS (OR = 1.71, 95% CI 0.87–3.34, P = 0.14). Pre-ART clinical findings that were associated with IRIS included hepatomegaly (OR = 1.36, 95% CI 0.63–2.93, P = 0.033) or lymphadenopathy (OR = 2.76, 95% CI 1.39–5.46, P = 0.005) prior to ART initiation (Table 3). At the study visit, clinical symptoms associated with IRIS included having cough (OR = 3.24, 95% CI 1.63–6.47, P = 0.001) or skin lesions (OR = 2.00 95% CI 1.05–3.80, P = 0.025).
Preantiretroviral therapy laboratory parameters
The majority (70%) of study participants were severely immunosuppressed with a CD4+ cell percentage of 15 or less and these children were more likely to develop IRIS (OR = 1.00, 95% CI 1.07–4.82, P = 0.033) when compared with those with a CD4+ cell percentage of at least 15 at ART initiation (Table 4). Study participants with 1000 or less CD8+ cells/μl were more likely to develop IRIS (OR = 3.60, 95% CI 1.70–7.63, P < 0.001). One hundred and seventeen (74%) of the children were anemic at the time of ART initiation. Of these 90 (77%) developed IRIS. However, anemia at ART initiation (OR = 1.39, 95% CI 0.66–2.92, P = 0.46) or any other pre-ART hematological indexes were not predictors of development of IRIS in this study population.
Laboratory and immunologic profile at study visit
At the study visit, 55% (87/162) of study participants were anemic with a hemoglobin level below 11.5 g/dl. Thrombocytopenia was found in five patients. Anemia (OR = 2.17, 95% CI 1.12–4.19, P = 0.023) at interview on ART was associated with IRIS on univariate but not multivariate analysis. All patients had a malaria blood smear performed with only 2% (3/162) having detectable parasitemia.
Children with an increase of at least 25 CD4+ T cells per microliter at time of the study visit from the pre-ART baseline were more likely to have IRIS (OR = 3.30, 95% CI 1.40–7.78, P = 0.005) (Table 4). HIV-1 viral loads were decreased from baseline with a median of 501 HIV RNA copies per milliliter (range <40–7 800 000 copies/ml) at the study visit. Of the 82 children who had viral loads measured, only four achieved undetectable plasma viral suppression (<40 copies/ml) at a median time on ART of 11.5 weeks.
Risk factors associated with immune reconstitution inflammatory syndrome
On multivariate analysis, the factors independently associated with IRIS were male sex, pre-ART CD4+ cell percentage of less than 15, study visit CD8+ cell absolute count below 1000 cells/μl, and cough at study visit (Table 5).
Despite numerous descriptions of the infectious and noninfectious causes of IRIS, the overall incidence remains largely unknown, particularly in many resource-limited areas and pediatric populations. There is no consensus on case definitions for IRIS in children, yet we continue to recognize probable IRIS-like presentations. We report a cross-sectional prevalence of IRIS of 38% during the first 6 months of ART in Uganda. The majority of these events (77%) would be considered unmasking IRIS manifestations. The vast majority of these events were atypical in having exaggerated clinical presentations, although the contribution of ongoing immunosuppression cannot be discounted. The overall, very important implication is that pediatric HIV care consists much more than simply delivering antiretroviral medications to children and that in the first few months of ART, subclinical infections are frequently unmasked. This should be an expectation for patients, their caregivers, healthcare workers, and policy makers.
The ability of comparison of this cross-sectional study with other cohorts is limited, as the majority of studies have been retrospective in design, focused on adults, or both, with a few exceptions . The prevalence of IRIS in this sub-Saharan African cohort appeared to be higher than the 23.4% IRIS prevalence in hospitalized Thai children . Another retrospective pediatric cohort study  reported an IRIS incidence of 20% among 91 children in Lima, Peru. Retrospective design has some limitations with incomplete documentation, leading to misclassification of such a relatively new entity as IRIS. Our study does match up similarly to the 41% incidence of probable and possible IRIS prospectively observed in a large adult cohort in Durban, South Africa .
The high prevalence of IRIS in this study population is possibly attributed to late presentation and a high background burden of subclinical infections. Diagnosis of HIV infection in infants is complicated, and in resource-limited areas often delayed, due to lack of diagnostic resources and lack of parental awareness of their own HIV status and thereby the infant's risk. The result is continued late presentation of HIV-infected children seeking HIV care only after developing advanced immunosuppression and presenting with one or more opportunistic infections. This is reflected in this study population, as the majority (70%) started ART with baseline CD4+ cell percentage below 15, indicative of severe immunosuppression and at risk of opportunistic infections. Second, in this resource-limited environment, children are frequently exposed to high background of infectious disease from opportunistic infections, environmental, and childhood vaccine-preventable diseases. In the absence of comprehensive pre-ART screening, subclinical infections are likely frequently present when starting ART.
In this study, the peak time of IRIS occurrence was within the first month of commencing ART. In the study by Shelburne et al. , most IRIS events presented in the first 60 days after ART initiation and in the Bakeera-Kitaka et al. study , the median time of occurrence of TB-IRIS was at 14 weeks. The probable reason why IRIS may occur earlier in children than adults is two-fold. First, children have a more robust improvement of their immune system with ART than adults, specifically children often achieve a 10-fold CD4+ T-cell increase, mainly of naive T cells . In our study, a rise of at least 25 CD4+ cells per microliter from baseline carried a three-fold risk of having an IRIS event, and the CD4 cell count increase was most marked in the first month on ART when most IRIS events occurred. Our analysis did not adjust for time on ART. Thus, even though IRIS patients had a shorter duration of ART than controls without IRIS, the CD4 response was more robust in IRIS patients.
Demographic factors also were associated with IRIS for both clear and unclear reasons. Increasing age was associated with IRIS, peaking in children who were 5–12 years of age. Age correlated with the degree of immunosuppression, thus on multivariate analysis, age was not an independent risk factor. Increasing age also represents increasing time at risk of TB exposure. Older children also had easier clinical history taking, making it easier to diagnose IRIS-related events. Sex was also associated with IRIS. In our study, the prevalence of IRIS in male children was higher and remained so in multivariate analysis. This is similar to that observed in the study by Shelburne et al.  who reported a 2.65-fold risk in males for IRIS, yet differs from other prospective adult cohorts in Africa [18,19]. The biological plausibility of sex as a risk factor for IRIS in children is unknown.
IRIS can manifest with a wide variety of clinical symptoms, depending on the target of the inflammatory response, thus the resulting clinical manifestation of IRIS depends on the prevailing infections in the locality. In our study, multiple and varied presentations of IRIS occurred. There were 86 clinical episodes of IRIS characterized as 18 distinct clinical scenarios, which occurred in 62 children. The clinical scenarios involved either unusual manifestations of a previously treated opportunistic infection or unmasking of a previously subclinical infection [1,16,19–22].
Mycobacterial-immune reconstitution inflammatory syndrome
Considering that Uganda is a high TB burden country, it was not surprising that unmasking TB-IRIS was the most common single clinical scenario of IRIS. The proportion of TB-IRIS events (29%) was similar to the proportion of mycobacterial-related IRIS observed in Thailand (44%) and Peru (35%) [8,15]. In adult studies, paradoxical TB-IRIS manifestations primarily occur within the first 3 months of ART and have been reported as fever, lymphadenitis, subcutaneous abscesses, pulmonary infiltrates, or inflammatory masses . In our pediatric cohort, the most common symptoms of TB-IRIS were fever, cough, and lymphadenopathy. The 15% overall incidence of ART-associated TB in this study was similar to adult studies [11,23–25], and similar to the 17% incidence previously reported by Bakeera-Kitaka et al.  from Kampala, Uganda, and higher than the 9% incidence reported in Chiang Mai, Thailand and 6.5% in Peru [9,15]. The higher prevalence of unmasking ART-associated TB in Uganda than in Thailand or Peru may reflect the increased burden of TB in sub-Saharan Africa.
Our finding that cough for more than 7 days at the time of enrollment was associated with IRIS is not surprising, as TB was the most common clinical infection. Uganda is in the top 15 TB burden countries globally with a high incidence of HIV–TB coinfection. Children are continually exposed to adults with TB, and those family members are also HIV infected.
Of the 25 children with mycobacterial-IRIS, three (2.1%) had clinical BCG-IRIS with ipsilateral lymphadenopathy with ulceration or abscess formation at the site of the BCG scar at time of the study visit. This has also been described in a South African pediatric cohort of children below 24 months with a higher 11.2% prevalence of BCG-IRIS . In restricting our cohort to children below 12 months, the prevalence of BCG-IRIS was 19% at time of the study visit. The overall incidence may have been higher.
Dermatologic immune reconstitution inflammatory syndrome
Little information exists on how ART affects the course of dermatologic conditions in children, whereas in adults, dermatological manifestations of IRIS appear to be the most frequent [16,19,27]. This study has demonstrated that dermatological manifestations were the most common IRIS events. Some of the types of dermatologic events such as paradoxical Kaposi sarcoma, molluscum contagiosum, and varicella zoster have been reported in adults [7,18].
Other manifestations were considered as unmasking IRIS events due to their unusual, exaggerated presentation. For example, three otitis media episodes presented with exaggerated purulent discharge in conjunction with immunologic success and viral suppression.
This vast clinical manifestation of IRIS depends on the prevailing infections in the locality of HIV care. Our study was interested in all manifestations of IRIS, thus the diverse presentations observed. In resource-limited areas where screening for opportunistic infections is primarily clinical, unmasking of subclinical opportunistic infections appears to be common.
Factors associated with immune reconstitution inflammatory syndrome
We neither find the type of ART regimen, pre-ART hemoglobin level, CD4+: CD8+ ratio, previous opportunistic infection, WHO stage III and IV, a shorter interval between initiating treatment for opportunistic infection, and starting ART, nor a rapid viral load decline to be associated with IRIS, as has been described in other adult cohorts [6,27].
The absolute CD8+ cells count at interview below 1000 cells/μl was associated with a four-fold risk of IRIS development. In a US study  of 120 adolescents, decreased CD8+ cell count was associated with a temporary clinical deterioration while on ART. In our population having a low CD8+ T-cell count correlated with older age.
There is no validated pediatric IRIS case definition to date, and this creates a challenge in diagnosing IRIS. This study used a prospective case definition in conjunction with expert opinion, similar to other recent studies [16,29]. Additionally, what is and is not ‘IRIS’ remains controversial in the absence of a gold standard; however, the adverse clinical events, whether labeled as IRIS or not, appear to be common in this multicentered prospective study. We believe these results are generalizable to other sub-Saharan pediatric populations presenting with advanced AIDS. The clinical implication is that pediatric HIV providers need to be aware of the frequent unmasking of subclinical and previously latent opportunistic infections within the first few months of initiating ART.
The design of the study was cross-sectional, thus IRIS events occurring prior to or after the study visit were not included. As such, the total incidence of IRIS cannot be estimated. A future prospective pediatric cohort study is needed in sub-Saharan Africa to better inform pediatric HIV care. Extrapolating solely from adult cohort studies on the incidence, risk factors, and pathogenesis of IRIS is unwise and may lead to incorrect assumptions regarding pediatric HIV-infected populations.
First, the prevalence of pediatric unmasking IRIS in this study was high and is likely to continue for the foreseeable future in the resource-limited countries as long as HIV maternal-to-child-transmission (MTCT) continues unabated coupled with children presenting late for HIV care with unknown, advanced immunosuppression. Second, there is need for rapid and early pediatric HIV diagnosis so as to facilitate early ART initiation in order to minimize the HIV-related morbidity and mortality , to which in part IRIS contributes. Third, there is need to re-emphasis vigorous TB screening to minimize unmasking of ART-associated TB, as this was the most common unmasked clinical infection. Fourth, providers should be aware of the frequent unmasking of subclinical infections in the first few months of ART and counsel caregivers. Finally, improved implementation of MTCT services is needed as a public health strategy to prevent IRIS through eradication of pediatric HIV.
JCRC receives support from the President's Emergency Plan For AIDS Relief. D.R.W. is supported by the National Institutes of Health (NAID K23AI073192–01A2).
The authors wish to acknowledge the incalculable contribution of the statistician Mr Yusuf Mulumba and Dr Okello Ayen; Department of Pediatrics and JCRC Laboratory, with special thanks to Drs Hilda Kizito, Abbas Lugemwa, William Kizito, and Francis Kiweewa; Department of Pediatrics and Child Health Makerere Medical School, with special thanks to Professor JK Tumwine, Dr Gerald Ojambo, and Professor Martyn French without whose assistance this study would not have been possible.
J.O. has full access to all the data in the study and takes responsibility for the integrity and accuracy of the data and data analysis. J.O., S.B.-K., P.M., and E.A.M. conceptualized and designed the study. Acquisition of data was done by J.O. and V.M. Statistical analysis was done by J.O. J.O., S.B.-K., and D.R.B. interpretated the data. Drafting of the manuscript was done by J.O. and D.R.B. Critical revisions for intellectual content were done by J.O., S.B.-K., and D.R.B. P.M. obtained the funding. Administrative, technical, or material support was provided by S.B.-K., P.M., and E.A.M.
There are no conflicts of interest.
1. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004; 38:1159–1166.
2. Resino S, Resino R, Maria Bellón J, Micheloud D, Gutiérrez MD, de José MI, et al
. Long-term effects of highly active antiretroviral therapy in pretreated vertically HIV type 1 Infected children: 6yrs of follow up. Clin Infect Dis 2006; 42:862–869.
3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al
. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853–860.
4. Michelet C, Arvieux C, François C, Besnier JM, Rogez JP, Breux JP, et al
. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998; 12:1815–1822.
5. Boulware DR, Callens S, Pahwa S. Pediatric HIV immune reconstitution inflammatory syndrome. Curr Opin HIV AIDS 2008; 3:461–467.
6. Murdoch DM, Venter WD, Van Rie A, Feldman C. Immune Reconstitution Syndrome (IRIS): review article of common infectious manifestations and treatment options. AIDS Res Therapy 2007; 4:9.
7. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC Jr, et al
. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19:399–406.
8. Puthanakit T, Aurpibul L, Oberdorfer P, Akarathum N, Kanjananit S, Wannarit P, et al
. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 44:599–604.
9. Puthanakit T, Oberdorfer P, Akarathum N, Wannarit P, Sirisanthana T, Sirisanthana V. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected Thai children. Pediatr Infect Dis J 2006; 25:53–58.
10. Bakeera-Kitaka S, Kekitiinwa A, Dhabangi A, Namulema E, Maganda A, Boulware DR. Tuberculosis immune reconstitution inflammatory syndrome among Ugandan children
. Int J Infect Dis
11. John L, Baalwa J, Kalimugogo P, Nabankema E, Castelnuovo B, Muhindo G, et al
. Response to ‘Does immune reconstitution promote active tuberculosis in patients receiving highly active antiretroviral therapy?’. AIDS 2005; 19:2049–2050.
12. Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, et al
. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr 2007; 7:13.
13. Achan J, Ruel T, Kateera F, Kalyango J, Akello C, Gasasira A, et al
. Immune reconstitution inflammatory syndrome in the first 6 months of antiretroviral therapy in HIV-infected Ugandan children
[abstract #MOPDB105]. 17th International AIDS Conference
; 8 August 2009; Mexico City, Mexico; 2009.
14. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18:1615–1627.
15. Wang ME, Castillo ME, Montano SM, Zunt JR. Immune reconstitution inflammatory syndrome in human immunodeficiency virus-infected children in Peru. Pediatr Infect Dis J 2009; 28:900–903.
16. Haddow LJ, Easterbrook PJ, Mosam A, Khanyile NG, Parboosing R, Moodley P, Moosa MY. Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort. Clin Infect Dis 2009; 49:1424–1432.
17. Sharland M, Watkins AM, Dalgleish AG, Cammack N, Westby M. Immune reconstitution in HAART-treated children with AIDS. Highly active antiretroviral therapy. Lancet 1998; 352:577–578.
18. Kambugu A, Meya DB, Rhein J, O'Brien M, Janoff EN, Ronald AR, et al
. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008; 46:1694–1701.
19. Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22:601–610.
20. Kumarasamy N, Chaguturu S, Mayer KH, Solomon S, Yepthomi HT, Balakrishnan P, et al
. Incidence of immune reconstitution syndrome in HIV/TB-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr 2004; 37:1574–1576.
21. Cheng VC, Yuen KY, Chan WM, Wong SS, Ma ES, Chan RM. Immune restitution disease involving the innate and adaptive response. Clin Infect Dis 2000; 30:882–892.
22. Stone SF, Price P, French MA. Immune restoration disease: a consequence of dysregulated immune responses after HAART. Curr HIV Res 2004; 2:235–242.
23. Manosuthi W, Van Tieu H, Mankatitham W, Lueangniyomkul A, Ananworanich J, Avihingsanon A, et al
. Clinical case definition and manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2009; 23:2467–2471.
24. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335–341.
25. Baalwa J, Mayanja-Kizza H, Kamya MR, John L, Kambugu A, Colebunders R. Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active antiretroviral therapy in Uganda. Afr Health Sci 2008; 8:190–195.
26. Smith K, Kuhn L, Coovadia A, Meyers T, Hu CC, Reitz C, et al
. Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS 2009; 23:1097–1107.
27. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42:418–427.
28. Flynn PM, Rudy BJ, Douglas SD, Lathey J, Spector SA, Martinez J, et al
. Virological and immunological outcomes after 24 weeks in HIV type-1 infected adolescents receiving HAART. J Infect Dis 2004; 190:271–279.
29. Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006; 42:1639–1646.
30. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al
. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359:2233–2244.
Keywords:© 2010 Lippincott Williams & Wilkins, Inc.
antiretroviral therapy/complications; children; HIV; immune reconstitution inflammatory syndrome